Lea Mertens
Clinical Researcher in Psychedelic Psychiatry
Data updated
Research Footprint
Lea Mertens appears in 12 tracked papers (2020–2026), most studied alongside Psilocybin, Placebo and LSD, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).
Most-cited paper: Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression (206 citations).
Frequent co-authors: Henrik Jungaberle, Gerhard Gründer and Max Wolff.
Background & Research
L. J. Mertens is an active researcher in contemporary psychedelic science with a focus on the clinical application and mechanistic study of psilocybin. Their work, represented across multiple papers and trial protocols, spans the design and rationale of randomised clinical trials for treatment‑resistant major depression (EPIsoDE), investigation of psychological processes that mediate therapeutic change (for example, reductions in experiential avoidance associated with decreased depression severity and suicidal ideation), and exploration of neural mechanisms (changes in amygdala–prefrontal functional connectivity during emotional processing following psilocybin treatment).
Mertens has also contributed to psychometric methodology through involvement in the development and validation of the Watts Connectedness Scale, and pursued translational preclinical questions such as the effects of psilocybin and LSD in animal models of alcohol relapse. Collectively, their contributions emphasise methodological rigour in trial design, measurement of psychological and neurobiological mechanisms of action, and bridging clinical and preclinical domains in psychedelic research. Publications and protocols list the author as L. J. Mertens; institutional affiliation and full given name were not available in the provided dataset.
Key Impact
Notable for contributing to clinical and translational psilocybin research, including trial design for treatment-resistant depression, mechanistic neuroimaging studies, development of psychometric tools, and preclinical investigations of psychedelic effects.
Collaboration Network
23 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Lea Mertens is associated with.
Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg
The Central Institute of Mental Health (Zentralinstitut für Seelische Gesundheit, ZI) is a psychiatric research and treatment center in Mannheim affiliated with the Medical Faculty Mannheim of Heidelberg University, providing research, teaching and clinical services in psychiatry, psychotherapy, child and adolescent psychiatry, psychosomatic medicine and addiction medicine.
View stakeholder →MIND Foundation
Non-ProfitEuropean nonprofit research and implementation organization that organizes the INSIGHT Conference and allied public/professional events.
View stakeholder →